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Several studies have indicated the existence of direct effects of melatonin on platelets. Here we show
that, melatonin at high concentration is capable of signiﬁcantly raising platelet intracellular calcium
even in the absence of an agonist. The effect of melatonin on platelets was abolished by luzindole, a
melatonin receptor blocker, and rotenone, while it was unaffected by cell-permeable antagonists of
either inositol 1,4,5-trisphosphate (IP3) receptor, phospholipase C (PLC), or baﬁlomycin A1, which
discharges acidic calcium stores. Melatonin-induced manganese entry provided evidence for activa-
tion of bivalent cation entry. Thus, our data suggest that melatonin evoked the elevation of platelet
intracellular calcium through depletion of mitochondrial Ca2+ stores and store-operated calcium
entry (SOCE), while the action was independent of the PLC-IP3 axis.
 2011 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Intracellular calcium regulates major platelet functions includ-
ing shape change, spreading, adhesion, aggregation and ﬁnally
thrombus formation [1–3]. Platelet agonists increase cytosolic
[Ca2+] by two mechanisms: release of Ca2+ from intracellular stores
and entry of extracellular Ca2+ through plasma membrane chan-
nels. Store-operated calcium entry (SOCE) is a process controlled
by calcium concentration in platelet dense tubular system (DTS),
the analogue of sarcoplasmic reticulum (SR) or endoplasmic retic-
ulum (ER). Depletion of DTS calcium stores triggers the activation
of SOCE channels, in the plasma membrane [4]. Besides, mitochon-
dria have also been implicated in maintaining cellular Ca2+ homo-
eostasis [5–8]. Recent works of Rosado have provided compelling
evidence in favor of platelet acidic organelles, including lysosomes
and lysosome-related organelles, as additional Ca2+ stores [9,10].
Melatonin (N-acetyl 5-methoxytryptamine) is a hormone
secreted by the pineal gland in brain, which regulates biological
rhythm. Several studies have implicated existence of direct effects
of melatonin in peripheral organs like platelets. Brain is not
directly accessible to observation in human beings when alive.
Moreover, studies on cerebrospinal ﬂuid are subject to ethical
consideration. Neurons and platelets share common structure
and functional characteristics that have led researchers to use
platelets as ‘peripheral’ model of neurons [11]. It is reported thatchemical Societies. Published by Emelatonin at physiological level (less than 1 lM) potentiates
aggregation, whereas at concentrations higher than 10 lM, it
attenuates aggregation induced by agonists like collagen, ADP
and epinephrine [12–14] involving cyclooxygenase pathway [15].
Melatonin exerts biological actions through the activation of two
G protein-coupled receptors, MT1 and MT2 [16,17]. In addition,
melatonin interacts with intracellular proteins such as calmodulin,
calreticulin or tubulin and antagonizes the binding of Ca2+ to cal-
modulin [18]. Melatonin binding sites have been characterized in
platelets from guinea pig [19] as well as human origin [20]. Besides
its well recognized central action on circadian biological rhythm,
melatonin has also been shown to modulate activities of cardiovas-
cular system and regulate platelet function. [12]. A recent study by
Rosado and his colleagues demonstrated that, melatonin implants
enhance thrombin evoked calcium ﬂux in platelets from vacci-
nated sheep [21]. Effect of melatonin on intracellular cAMP accu-
mulation reported in nerve tissues or cell lines transfected with
melatonin receptors were mostly inhibitory. However, potentiat-
ing actions on adenylate cyclase have also been reported [22]. In
human platelets, melatonin has inhibitory effect on prostacyclin-
stimulated cAMP accumulation in vitro [13].
Melatonin supplements help prevent jet lag, particularly in peo-
ple who cross ﬁve or more time zones. It may also help with sleep
problems associated with menopause. Gels, lotions, or ointments
containing melatonin may protect against sunburn and other skin
damage. In this study, we report for the ﬁrst time that pharmaco-
logical dose of melatonin elevates intracellular free calcium in
human platelets. Rise in cytosolic Ca2+ is central to platelet
activation, which triggers signaling events leading to thrombuslsevier B.V. All rights reserved.
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infarction and stroke [5,23]. Bach et al. have shown involvement
of second messengers, inositol 1,4,5-trisphosphate (IP3) and
[Ca2+]i in the signaling induced by melatonin in rat insulinoma
INS1 cells [24]. Recently, it has been revealed that exogenous mel-
atonin releases Ca2+ from intracellular stores in exocrine pancreatic
cell lines [25]. We show here that, melatonin-induced rise in [Ca2+]i
in platelets was not precluded by cell-permeable antagonists of IP3
or phospholipase C (PLC) , signifying a signaling mechanism unre-
lated to IP3-PLC signaling axis. Capacitative cation inﬂux was con-
ﬁrmed from melatonin-induced entry of extracellular MnCl2 into
platelets. Our results also indicated that melatonin evoked rise in
[Ca2+]i in platelets pretreated with baﬁlomycin A1, which dis-
charges acidic stores, but not with rotenone that releases Ca2+ from
mitochondrial stores. These ﬁndings suggested that melatonin elic-
ited rise in platelet cytosolic calcium by stimulating release from
mitochondrial stores, as well as stimulating SOC entry.
2. Materials and methods
Fura 2/AM was obtained from Calbiochem. 2-APB
(2-aminoethoxydiphenyl borate), U73122, luzindole, dibutyryl
cAMP, melatonin, EGTA, thapsigargin, rotenone, baﬁlomycin A1,
MnCl2 and aspirin were the products of Sigma.
2.1. Platelet Preparation
Blood from healthy volunteers, who had denied taking medica-
tion in the previous 2 weeks, was collected in citrate phosphate
dextrose and centrifuged at 180 g for 10 min. The supernatant
(platelet-rich plasma or PRP) was incubated with 1 mM acetylsal-
icylic acid for 15 min at 37 C. After addition of EDTA (5 mM),
PRP was centrifuged at 600 g for 10 min. Cells were washed in buf-
fer A (20 mM HEPES, 138 mM NaCl, 2.9 mM KCl, 1 mM MgCl2,
0.36 mM NaH2PO4 and 1 mM EGTA, supplemented with 5 mM glu-
cose). Platelets were ﬁnally suspended in buffer B which was same
as buffer A but without EGTA. The ﬁnal platelet count was adjusted
to 3–4  108/ml. Handling and mixing was done gently in order to
prevent activation of platelets.
Wherever indicated, platelets were preincubated at 37 C for
10 min with following inhibitors: U-73122 (10 lM), 2-APB
(100 lM), luzindole (500 lM) and dibutyryl cAMP (5 mM) etc.
2.2. Measurement of intracellular free calcium
PRP was incubated with 2 lM Fura-2 AM for 45 min at 37 C in
the dark. The Fura 2-loaded platelets were washed and resus-
pended in buffer B at 1  108 cells/ml. Fluorescence was recordedFig. 1. Melatonin raises free intracellular Ca2+ in human platelets. (a) Fura 2-loaded plate
by addition of 500 lM melatonin. Intracellular calcium was measured as described. (b)
compared to melatonin induced platelets in EGTA set; #P < 0.05 as compared to vehiclein 400 ll aliquots of platelet suspensions, both control as well pre-
treated with melatonin, at 37 C under non-stirring condition.
Excitation wavelengths were 340 and 380 nm and emission wave-
length was set at 510 nm in Hitachi ﬂuorescence spectrophotome-
ter (model F-2500). Changes in intracellular free calcium
concentration, [Ca2+]i, upon treatment with thrombin and melato-
nin were monitored from the ﬂuorescence ratio (340/380) using
Intracellular Cation Measurement Program in FL Solutions soft-
ware. Fmax was determined by lysing the cells with 40 lMdigitonin
in the presence of saturating CaCl2 .Fmin was determined by the
addition of 2 mM EGTA. Intracellular free calcium was calibrated
according to the derivation of Grynkiewicz et al. [26].
2.3. Statistical methods
Standard statistical methods were employed. Parametric meth-
ods (t test) were used for evaluation and signiﬁcance tests were
considered signiﬁcant at P less than 0.05 (2-tailed tests). Data were
presented as means ± SD of at least ﬁve individual experiments
from different blood donors.
3. Results
3.1. Melatonin elevates free intracellular Ca2+ in human platelets
As platelet activation is associated with increase in the concen-
tration of cytosolic calcium [27], we examined effect of melatonin
on intracellular calcium ﬂux. Incubation of platelets with melato-
nin at concentration below 100 lM did not affect basal calcium le-
vel in resting human platelets. However, rise in melatonin
concentration led to dose-dependent increase in level of intracellu-
lar calcium. To understand whether the observed rise in cytosolic
Ca2+ has extracellular or intracellular origin, we performed the
experiment either in presence of 1 mM calcium or 1 mM EGTA, fol-
lowed by addition of melatonin (500 lM) (Fig. 1). When extracel-
lular Ca2+ was chelated by EGTA, melatonin induced a minor
increase in [Ca2+] from 100 nM to 200 nM, indicative of release
from intracellular stores. However, presence of 1 mM extracellular
Ca2+ evoked a stronger rise in cytosolic Ca2+ from 140 nM to
400 nM consistent with entry from external source.
3.2. PLC-IP3 axis is not involved in melatonin-induced calcium rise
Intracellular mobilization of calcium in DTS of platelets is med-
iated through IP3 receptors [28]. So, we asked whether PLC–IP3
axis was responsible for the rise in calcium in response to melato-
nin in absence of extracellular Ca2+. We reasoned that, melatonin
treatment might induce activation of platelet PLC leading tolets were preincubated for 5 min with either 1 mM calcium or 1 mM EGTA, followed
The bar diagram shows an average of ﬁve independent experiments. (⁄P < 0.05 as
)
Fig. 2. PLC-IP3 axis is not involved in melatonin-induced rise in cytosolic calcium. (a) Fura 2-loaded platelets were incubated for 10 min with either 2-APB or U73122, in
presence of 1 mM EGTA, followed by addition of 500 lM melatonin. Intracellular calcium was measured as described. (b) The bar diagram shows an average of ﬁve
independent experiments.
Fig. 3. Rise in intracellular Ca2+ by melatonin was attenuated by luzindole, a melatonin receptor antagonist. (a) Fura 2-loaded platelets were incubated for 10 min with
luzindole (500 lM) followed by stimulation with melatonin (500 lM). (b) The bar diagram shows an average of ﬁve independent experiments (⁄P < 0.05 as compared to
melatonin-induced platelets).
Fig. 4. Melatonin potentiated thrombin-induced rise in intracellular calcium. (a) Fura 2-loaded platelets were incubated for 10 min with melatonin (500 lM) followed by
stimulation with thrombin (1 IU/ml). (b) The bar diagram shows an average of ﬁve independent experiments. (⁄P < 0.05 as compared to thrombin-induced platelets)
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stores.
Platelets were separately incubated with 2-APB (100 lM) (an
IP3 antagonist), U73122 (10 lM) (inhibitor of PLCb) or the vehicle,
followed by addition of melatonin (500 lM). EGTA was included in
the suspension medium to prevent calcium entry from extracellu-
lar source. None of the inhibitors could inﬂuence the action of mel-
atonin on platelet calcium (Fig. 2), thus ruling out the involvement
of PLC-IP3 pathway as a possible underlying mechanism.3.3. Rise in platelet intracellular Ca2+ by melatonin is attenuated by
luzindole, a melatonin receptor antagonist
Next we asked whether melatonin evoked rise in intracellular
calcium is by interaction with speciﬁc receptors on platelet surface.
Platelets were incubated with luzindole (500 lM), a melatonin
receptor antagonist, followed by addition of the hormone in pres-
ence of 1 mM extracellular calcium. Melatonin-induced rise in
cytosolic calcium was found to be abolished completely by
Fig. 5. Effect of melatonin on platelets was not regulated by level of cytosolic cAMP. (a) Fura 2-loaded platelets were incubated for 10 min with dibutyryl cAMP (5 mM)
followed by treatment with melatonin (500 lM)) or thrombin (1U/ml). (b) the bar diagram shows an average of ﬁve independent experiments (⁄P < 0.05 as compared to
thrombin-induced platelets).
Fig. 6. Melatonin exhibited thapsigargin-like properties. (a) Melatonin (500 lM) was added to Fura 2-loaded platelets, followed by addition of 1 mM calcium after 150 s. (b)
Melatonin (500 lM) was added to Fura 2-loaded platelets, followed by addition of 2 mM MnCl2 after 200 s. Fluorescence ratio was measured as described. Traces shown are
representative of at least ﬁve separate experiments.
Fig. 7. Melatonin-induced calcium rise was not associated with inhibition of SERCA.
Thapsigargin (1 lM) was added to Fura 2-loaded platelets, followed by addition of
melatonin (500 lM). Fluorescence ratio was measured as described. Traces shown
are representative of at least ﬁve separate experiments.
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were receptor-dependent.
3.4. Melatonin potentiates thrombin-induced rise in intracellular
calcium
In order to enquire any synergistic effect of melatonin with
thrombin, a physiological agonist of platelets, cells were ﬁrst incu-
bated with the hormone (500 lM) followed by thrombin (1 IU/ml)
in presence of extracellular calcium, and cytosolic calcium ﬂux was
studied. As expected, thrombin alone induced signiﬁcant increase
in intracellular [Ca2+]i. Melatonin was found to signiﬁcantly
potentiate the effect of thrombin (Fig. 4). The initial rise in calcium
and the following plateau were nearly 2 times higher in melatonin-
pretreated platelets than in presence of thrombin alone. This
observation was consistent with the earlier report that melatonin
reduced lag phase and increased calcium mobilization in throm-
bin-activated sheep platelets [21].
3.5. Effect of melatonin on platelets is not regulated by level of
cytosolic cAMP
Melatonin is known to decrease cAMP level in target cells [29].
In platelets decrease in cytosolic cAMP is associated withsigniﬁcant enhancement in agonist-induced platelet activation
and rise in intracellular calcium [30]. Hence, we next asked
whether increasing level of intracellular cAMP will attenuate mel-
atonin effect on cytosolic calcium in platelets. When platelets were
Fig. 8. Cytosolic Ca2+ ﬂux in melatonin-treated platelets was regulated by mitochondrial source of calcium and was independent of acidic stores. Fura 2-loaded platelets were
incubated for 10 min either with baﬁlomycin A (1 lM) or with rotenone (20 lM), followed by addition of melatonin (500 lM)) Fluorescence ratio was measured as described.
Traces shown are representative of at least ﬁve separate experiments.
Fig. 9. Melatonin had no effect on thrombin-mediated platelet aggregation.
Platelets were pre-incubated with either melatonin (500 lM) or vehicle for
15 min under stirring, followed by addition of thrombin (0.5 U/ml) in certain
experiments, as indicated. Traces shown are representative of at least ﬁve separate
experiments.
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log of cAMP, for 10 min at room temperature, thrombin-mediated
platelet aggregation (not shown) or rise in intracellular calcium
(Fig. 5) was completely inhibited. However, dibutyryl cAMP pre-
treatment did not affect melatonin-induced rise in cytosolic cal-
cium (Fig. 5).
3.6. Stimulation of SOC entry by melatonin
As stated earlier, melatonin elicited moderate increase in plate-
let intracellular Ca2+ in IP3-independent manner. When cells were
suspended in Ca2+-free medium, subsequent addition of 1 mM
CaCl2 to the medium brought about a further strong rise in intra-
cellular calcium indicative of SOCE (Fig. 6a). Thus, it could be sur-
mised that melatonin depleted intracellular Ca2+ stores in a
manner resembling the action of thapsigargin [31] and led to stim-
ulation of SOCE.
The external cation inﬂux was further examined in the presence
of Mn2+. The ion penetrates across plasma membrane of stimulated
platelets to bind with fura-2, which results in quenching of fura-2
ﬂuorescence. When MnCl2 was added to platelet suspension 1 min
after melatonin, decrease in ﬂuorescence was recorded (Fig. 6b),
consistent with bivalent cation entry activated by melatonin.
3.7. Melatonin-induced calcium rise is not associated with inhibition of
SERCA
In order to understand whether the observed effects of melato-
nin were attributable to suppression of SERCA activity, we pre-
incubated platelets with high dose of thapsigargin (1 lM) to inhibit
the SERCA isoforms, namely SERCA2b (on platelet DTS) and SER-
CA3 (on acidic Ca2+ store) [10], followed by addition of melatonin.
As expected, thapsigargin elicited a rise in intracellular calcium,
which was further augmented in presence of melatonin (Fig. 7).
This ruled out the possibility that melatonin-induced rise in cyto-
solic Ca2+ could be brought about by inhibition of SERCA isoforms
by the hormone.
3.8. Melatonin induces release of Ca2+ from mitochondria and not from
acidic organelles in platelets
As melatonin-induced calcium rise was not associated with
inhibition of SERCA and IP3-mediated pathway ruling out involve-
ment of DTS, we asked whether acidic organelles might be the
source of calcium releasable by melatonin. We pre-incubatedplatelets with baﬁlomycin A1 (1 lM), inhibitor of vacuolar type
H+-ATPase that releases calcium from acidic granules, followed
by addition of melatonin (Fig. 8). Our results indicated that prein-
cubation with baﬁlomycin A1 did not alter Ca2+ release induced by
melatonin.
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atonin action, we performed the experiments in the presence of
rotenone (20 lM) that dissipates mitochondrial transmembrane
potential and releases Ca2+ from the organelle. Subsequent addi-
tion of melatonin did not bring about further increase in [Ca2+]i,
thus indicative of mitochondrial contribution to calcium rise elic-
ited by melatonin (Fig. 8). However, signaling path linking mela-
tonin to depletion of mitochondrial calcium store remains
unknown.
3.9. Melatonin has no effect on thrombin-induced platelets
aggregation
In order to examine the effect of melatonin on thrombin-
mediated platelet aggregation, thrombin (0.5 U) was added to
platelets pretreated with melatonin or vehicle. Thrombin evoked
robust aggregation in control platelets. There was no change in
the aggregation proﬁle when platelets were pre-incubated with
melatonin (Fig. 9). However, melatonin alone was also found to
elicit minor wave of platelet aggregation (Fig. 9).4. Discussion
In the present study, we show that melatonin alone, at higher
concentration reachable by pharmacological doses, induced rise
in intracellular calcium in resting platelets, as well as potentiated
the effect of thrombin in raising platelet calcium but had no effect
on thrombin -induced platelet aggregation. Platelets elevate cyto-
solic calcium by release from compartmentalized intracellular
stores or by facilitating entry from outside through plasma mem-
brane channels. In resting cells low cytosolic calcium is maintained
by action of different Ca2+-ATPases and exchangers in synergy,
which act by Ca2+ sequestration into the stores and extrusion
across the plasma membrane [32]. SERCA isoforms present on
the membranes of DTS as well as acidic Ca2+ stores are responsible
for store reﬁlling that in turn results in termination of SOCE [10,3].
Effect of melatonin on platelet cytosolic calcium was com-
pletely abolished in presence of luzindole (Fig. 3), a known antag-
onist of melatonin receptor, which was suggestive hormone acting
through its receptors on platelet membrane. Although melatonin is
known to lower cAMP in target cells, raising cytosolic cAMP by its
non-hydrolyzable analog did not modify the effect of melatonin on
platelets, thus ruling out participation of this nucleotide in the spe-
ciﬁc signaling pathway. Melatonin could raise cytosolic calcium
either by inducing release from intracellular stores or facilitating
entry from extracellular milieu. In our experiment, melatonin-in-
duced rise in calcium was signiﬁcantly reduced by chelation of
extracellular calcium by EGTA. To test whether PLC was stimulated
in melatonin-treated platelets leading to generation of IP3 and sub-
sequent release of calcium from IP3-sensitive stores, we separately
pre-incubated platelets with antagonists of PLC and IP3 receptor,
followed by treatment with melatonin. None of the inhibitors
could inﬂuence the action of melatonin on platelet calcium
(Fig.2), therefore ruling out the involvement of PLC-IP3 axis as a
possible mechanism. Melatonin was found to induce rise in
[Ca2+]i even after platelet SERCA isoforms were inhibited by thapsi-
gargin (Fig. 7), thus excluding the role SERCA inhibition in melato-
nin function. Melatonin evoked rise in [Ca2+]i in platelets
pretreated with baﬁlomycin A1 but not with rotenone, which
was consistent with major contribution of mitochondrial calcium
stores in eliciting the melatonin effect. Melatonin-induced manga-
nese entry in platelets was suggestive of activation of bivalent cat-
ion entry by the hormone. Taken together, both mitochondria and
SOCE contributed to melatonin-induced calcium increase in
platelets.Melatonin is often prescribed in therapeutic form to ease
insomnia, combat jet lag, protect cells from free-radical damage
and boost immune system [33]. It has been demonstrated to be
effective in the treatment of many circadian rhythm sleep disor-
ders [34] and used as a medication for sleep disturbance in depres-
sion, treatment of psychiatric disorders and as a skin protector for
ultraviolet light [35]. Melatonin has also been shown to be effec-
tive in ﬁbromyalgia [36]. Short term side effects of the therapy in-
clude vivid, frightening nightmares, headaches and mild
depression, along with morning grogginess and confusion [37]. In
a recent clinical study a dose as high as 2 mg extended-release
melatonin has been administered every night to insomniac pa-
tients for a period of 3 weeks [38]. Melatonin is considered a die-
tary supplement and mostly available as an alternative medicine
without formal prescription and dosage regulation. As with all
non-regulated supplements, there has been no substantial study
to document adverse effects of melatonin from its long term use
or from intake of higher dose. So our present study should add a
cautionary note to unchecked and unregulated melatonin therapy.
Earlier reports have suggested inhibitory effects of melatonin
on agonist-induced platelet aggregation and secretion [12]. How-
ever, we show here that, melatonin, at higher concentration reach-
able by therapeutic doses, is capable of signiﬁcantly raising platelet
intracellular calcium even in absence of any agonist, while it syn-
ergizes the effect of platelet agonists. Recently, it has been shown
that exogenous melatonin elevates [Ca2+]i in pancreatic AR42 J
cells, which facilitates release of digestive enzymes downstream
of physiological secretagogues [24]. We show here that, melato-
nin-induced rise in [Ca2+]i in platelets was not prevented by cell-
permeable antagonists of IP3 or PLC, suggestive of signaling mech-
anism unrelated to IP3-PLC axis. Our results supported that melato-
nin released calcium from the mitochondrial source that is known
to play minor role in intracellular calcium homeostasis in platelets.
As platelet is a critical player in arterial thrombosis leading to
ischemic pathologies like coronary heart disease and stroke, and
intracellular calcium being a major determinant of platelet reactiv-
ity, any therapeutic use of melatonin should be monitored under
intense caution.
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